docturnal
Docturnal is a point-of-care screening and diagnostics solution provider established in April 2016, focusing on lung health, particularly infectious diseases and lung cancer. Their flagship product, TimBre™, offers non-invasive, real-time acoustic cough testing for Tuberculosis (TB) screening and diagnostics, aiming to be fast, affordable, and accurate. Docturnal's product portfolio also extends to solutions for Pneumonia and COPD/Asthma, with ongoing development for Lung Cancer screening. The company emphasizes its approach as a cost-effective and highly accurate method (91% accuracy, 98% cost-effective) to improve early detection and accessibility for underserved populations. Docturnal actively partners with organizations like Molbio Diagnostics and pharmaceutical companies to enhance its product offerings and expand its research, supported by grants such as the USISTEF grant for developing new screening solutions.
docturnal
Docturnal is a point-of-care screening and diagnostics solution provider established in April 2016, focusing on lung health, particularly infectious diseases and lung cancer. Their flagship product, TimBre™, offers non-invasive, real-time acoustic cough testing for Tuberculosis (TB) screening and diagnostics, aiming to be fast, affordable, and accurate. Docturnal's product portfolio also extends to solutions for Pneumonia and COPD/Asthma, with ongoing development for Lung Cancer screening. The company emphasizes its approach as a cost-effective and highly accurate method (91% accuracy, 98% cost-effective) to improve early detection and accessibility for underserved populations. Docturnal actively partners with organizations like Molbio Diagnostics and pharmaceutical companies to enhance its product offerings and expand its research, supported by grants such as the USISTEF grant for developing new screening solutions.